Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo

Not Applicable

• Conditions: Autophagy

• Registration Number: NCT03371758
• Lead Sponsor: Cairo University

Brief Summary

The exact mechanism of impairment of autophagy in vitiligo has not yet been determined.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-01
• Study First Submitted: 2017-12-05
• Study First Submitted QC: 2017-12-08
• Study First Posted: 2017-12-13
• Status Verified: 2018-01
• Last Update Submitted: 2018-01-19
• Last Update Posted: 2018-01-23
• Primary Completion: 2018-05
• Study Completion: 2018-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• • Patients with non-segmental vitiligo whether active or stable.

  • Age above 12 years.
  • Both sexes.

Exclusion Criteria

• • Patients should not use any topical or systemic treatment at least 6 weeks before inclusion into the study.

  • Patients having other autoimmune disease, heart disease, liver disease, kidney disease, neurological disorder, cancer, active infection or any chronic disease.
  • Pregnancy or breast feeding for female patients.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Expression of LC3-I, LC3-II & Beclin 1 in vitiligo patients	1 year

Trial Locations

Locations (1)

Maha Fathy Elmasry; 🇪🇬 Cairo, Egypt